Citations 1
Capecitabine/ irinotecan (CapIri) and capecitabine/oxaliplatin (CapOx) are active second-line protocols in patients with advanced colorectal cancer (ACRC) after failure of first-line combination therapy: Results of a randomized phase II study
Grothey, Axel, Jordan, Kim , Kellner, O, Dietrich, Georg , Kroening, Hendrik, Schlichting, C., Forstbauer, Helmut , Constantin, Carolina , Mantovani, LG , Schmoll, Hans‐Joachim
Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 3534-3534
